Welcome to our dedicated page for Semler Scientific news (Ticker: SMLR), a resource for investors and traders seeking the latest updates and insights on Semler Scientific stock.
Semler Scientific, Inc. (SMLR) combines cutting-edge healthcare diagnostics with innovative financial strategies, making it a unique player in medical technology and digital asset management. This news hub provides investors with essential updates on the company's FDA-cleared QuantaFlo® system and its disciplined bitcoin treasury approach.
Find timely press releases covering regulatory milestones, product developments, earnings reports alongside strategic financial decisions. Our curated collection helps stakeholders track both medical innovations and digital asset performance metrics like BTC Yield - crucial for understanding SMLR's dual-focused value proposition.
Key updates include chronic disease management advancements, cardiovascular diagnostic innovations, and treasury strategy evolution. Bookmark this page for centralized access to SMLR's latest operational developments and financial disclosures, enabling informed analysis of its healthcare technology leadership and digital asset integration.
Semler Scientific (OTCQB: SMLR) reported a significant financial uplift for Q2 and H1 2021. Revenues surged to $14.3 million, marking a 125% increase from $6.4 million year-over-year. Net income also rose sharply by 522% to $6.7 million, with earnings per share reaching $1.00. The company holds $28.5 million in cash and aims for continued profitability and growth in the expanding peripheral arterial disease (PAD) testing market.
Semler Scientific, Inc. (SMLR) announced it will report its financial results for the second quarter and first half of 2021 on August 2, 2021, after U.S. markets close. The conference call will be hosted by CEO Doug Murphy-Chutorian at 4:30 PM ET, alongside senior finance and marketing executives. Semler focuses on technology solutions to enhance healthcare efficiency, having launched QuantaFlo®, a point-of-care test for diagnosing peripheral arterial disease. This test helps evaluate patient risk for heart attacks and strokes, aligning with Semler's mission to support better patient care.
Semler Scientific, Inc. (OTCQB: SMLR), based in Santa Clara, California, announced that CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present an overview at the Raymond James Human Health Innovation Conference on June 22, 2021, at 12:00 pm ET. A live webcast of the presentation will be available on the company's website under "Events and Presentations". Semler focuses on technology solutions that enhance healthcare efficiency, including its FDA-cleared product, QuantaFlo®, designed for diagnosing peripheral arterial disease.
Semler Scientific (SMLR) reported a strong Q1 2021 with revenues of $13.2 million, up 40% from Q1 2020's $9.4 million. The company achieved a 74% increase in pre-tax net income to $6.0 million, translating to $0.73 per basic share. Cash reserves rose to $26.5 million, marking a substantial $15.3 million increase. Future growth is anticipated as Semler enters a distribution agreement worth $2.0 million for product inventory. The company aims to outpace expense growth while maintaining profitability.
Semler Scientific, Inc. (OTCQB: SMLR) announced it will report its first-quarter financial results for 2021 on May 3, 2021, after market close. A conference call will be hosted by CEO Doug Murphy-Chutorian at 4:30 PM ET the same day, alongside senior financial executives. Semler focuses on technology solutions to enhance healthcare provider efficiency and has a history of FDA-cleared products like QuantaFlo®, which helps assess cardiovascular risks. This upcoming announcement may provide insights into the company’s financial health and future outlook.
Semler Scientific, Inc. (OTCQB: SMLR) announced that CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 4:30 pm ET. They will also engage in one-on-one calls with investors. A live webcast will be accessible under the "Events and Presentations" section of the Semler Scientific website. The presentation will be archived for 90 days.
Semler specializes in technology solutions for healthcare providers, focusing on chronic disease evaluation and management, including its FDA-cleared product QuantaFlo®.
Semler Scientific (SMLR) reported strong financial results for the year ended December 31, 2020. Revenues rose to $38.6 million, reflecting an 18% increase from $32.8 million in 2019. Pre-tax net income surged 54% to $16.5 million with a 43% margin. However, net income fell 7% to $14.0 million due to a prior year's tax benefit. The company’s cash position improved significantly, reaching $22.1 million. Looking to 2021, Semler anticipates continued profitability amid challenges posed by COVID-19 regulations.
Semler Scientific, Inc. (SMLR) announced its participation in the H.C. Wainwright Global Life Sciences Conference. CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present a company overview on March 9, 2021, accessible on-demand at semlerscientific.com/hcwr-global. Additionally, management will engage in one-on-one investor calls on March 10. Semler specializes in technology solutions for improving clinical effectiveness, focusing on chronic disease evaluation.
Semler Scientific, Inc. (OTCQB: SMLR) announced it will release financial results for Q4 and the full year ended December 31, 2020, on March 1, 2021, after U.S. markets close. CEO Doug Murphy-Chutorian will host a conference call at 4:30 PM ET the same day, joined by senior finance officials. Participants are encouraged to pre-register for immediate access to the call. Semler Scientific focuses on technology solutions that enhance healthcare provider effectiveness and efficiency and has received FDA clearance for its flagship product QuantaFlo®, aiding in diagnosing peripheral arterial disease.
Semler Scientific, Inc. (SMLR), based in San Jose, California, announced participation in several upcoming virtual investor conferences in September 2020. The events include the 5th Annual Colliers Securities Conference on September 10, the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 15, and the 4th Annual Best Ideas Growth (BIG4) Conference on September 17. The company focuses on improving healthcare efficiency with technology solutions, notably its QuantaFlo® product, which assists in diagnosing peripheral arterial disease.
FAQ
What is the current stock price of Semler Scientific (SMLR)?
What is the market cap of Semler Scientific (SMLR)?
